Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase II Trial of High-Dose MTX + Ara-C ± Thiotepa ± Rituximab, Followed by Brain Irradiation vs. High-Dose Chemotherapy with ASCT in Primary CNS Lymphoma
DRKS00003763Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of methotrexate, cytarabine, thiotepa, rituximab, carmustine and 1 more in primary central nervous system lymphoma (PCNSL) (5 arms), sponsored by Universitätsklinikum Freiburg. Started May 2012; status: completed.
02
Drugs
methotrexatecytarabinethioteparituximabcarmustine
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on DRKS00003763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003763.